Annexon Announces Pricing of $75 Million Public Offering of Common Stock and Pre-Funded Warrants

Core Viewpoint - Annexon, Inc. has announced a public offering of common stock and pre-funded warrants to raise approximately $75 million to advance its clinical platform targeting neuroinflammation in complement-mediated diseases [1][2]. Group 1: Offering Details - The public offering consists of 25,096,153 shares of common stock priced at $2.60 per share and pre-funded warrants for 3,750,000 shares at a purchase price of $2.599 per share [1]. - The gross proceeds from the offering are expected to be $75 million before deducting underwriting discounts and commissions [2]. - The offering is set to close on November 14, 2025, subject to customary closing conditions [2]. Group 2: Underwriters - Goldman Sachs & Co. LLC, TD Cowen, and Wells Fargo Securities are acting as joint book-running managers for the offering [3]. Group 3: Company Overview - Annexon, Inc. is focused on developing complement inhibitors to address neuroinflammation, targeting diseases affecting the body, brain, and eye [6]. - The company's approach centers on C1q, aiming to prevent tissue damage caused by misdirected inflammatory pathways [6]. - Annexon's pipeline includes investigational drug candidates across autoimmunity, neurodegeneration, and ophthalmology, addressing the needs of nearly 10 million people globally [6].